首页> 美国卫生研究院文献>British Journal of Cancer >Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre randomised phase II trial (ALTER0302)

【2h】

Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre randomised phase II trial (ALTER0302)

机译：安洛替尼作为难治性晚期非小细胞肺癌患者的三线治疗：一项多中心随机II期试验（ALTER0302）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: Anlotinib (AL3818) is a novel multitarget tyrosine kinase inhibitor, inhibiting tumour angiogenesis and proliferative signalling. The objective of this study was to assess the safety and efficacy of third-line anlotinib for patients with refractory advanced non-small-cell lung cancer (RA-NSCLC).

机译：背景：Anlotinib（AL3818）是一种新型的多靶酪氨酸激酶抑制剂，可抑制肿瘤血管生成和增殖信号。这项研究的目的是评估第三线安洛替尼对难治性晚期非小细胞肺癌（RA-NSCLC）患者的安全性和有效性。

著录项

期刊名称 British Journal of Cancer
作者
Baohui Han; Kai Li; Yizhuo Zhao; Baolan Li; Ying Cheng; Jianying Zhou; You Lu; Yuankai Shi; Zhehai Wang; Liyan Jiang; Yi Luo; Yiping Zhang; Cheng Huang; Qiang Li; Guoming Wu;
展开▼
作者单位

展开▼
年(卷),期 2018(118),5
年度 2018
页码 654–661
总页数 8
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
non-small-cell lung cancer multitarget tyrosine kinase inhibitor anlotinib third line;

机译：非小细胞肺癌;多靶点;酪氨酸激酶抑制剂;安洛替尼;第三线;

相似文献

外文文献
中文文献
专利

1. Randomized phase III trial of erlotinib versus docetaxel as second- Or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and erlotinib lung cancer trial (DELTA) [J] . KawaguchiT., AndoM., AsamiK., Journal of Clinical Oncology . 2014,第18期

机译：Orlotinib的随机阶段III试验与Docetaxel作为高级非小细胞肺癌患者的二线或第三线疗法：多西紫杉醇和厄洛替尼肺癌试验（Delta）
2. Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial [J] . Neal Joel W., Dahlberg Suzanne E., Wakelee Heather A., The lancet oncology . 2016,第12期

机译：厄洛替尼，卡博替尼或厄洛替尼加卡博替尼作为EGFR野生型晚期非小细胞肺癌（ECOG-ACRIN 1512）患者的二线或三线治疗：随机，对照，开放标签，多中心， 2期试验
3. A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology [J] . Booton R, Lorigan P, Anderson H, Annals of oncology: official journal of the European Society for Medical Oncology . 2006,第7期

机译：多西他赛/卡铂与丝裂霉素C /异环磷酰胺/顺铂（MIC）或丝裂霉素C /长春碱/顺铂（MVP）在晚期非小细胞肺癌患者中进行的III期临床试验：一项英国胸腔肿瘤学的随机多中心试验
4. The impact of the type of resection on survival in patients with N1 non-small-cell lung cancers [C] . Umit Aydogmus, Levent Cansever, Yasar Sonmezoglu, 21st international conference on screening for lung cancer . 2009

机译：切除类型对N1非小细胞肺癌患者生存的影响
5. The effectiveness of chemoradiation for stage III non-small-cell lung cancer patients at the Kingston Regional Cancer Center (Ontario). [D] . Sinclair, Suzanne Marie. 2003

机译：金斯敦地区癌症中心（安大略省）对III期非小细胞肺癌患者进行化学放射治疗的有效性。
6. A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy [O] . A Kotsakis, A Matikas, F Koinis, 2016

机译：卡巴他赛在多西他赛为基础的化疗后进展的晚期非小细胞肺癌患者的多中心II期试验中
7. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302) [O] . Baohui Han, Kai Li, Yizhuo Zhao, 2018

机译：Anlotinib作为难治性先进的非小细胞肺癌患者的第三线治疗：多期，随机期二期试验（ALTER0302）

Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre randomised phase II trial (ALTER0302)

摘要

著录项

相似文献

相关主题

期刊订阅